View in English:
February 4, 2023 6:09 pm

Pfizer, BioNTech’s updated booster protects against Omicron in human trial

October 14

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.

With the results, which the companies described as consistent with preclinical data, the partners are following up with human trial data that had previously been missing from their successful filings for regulatory

In a joint statement on Thursday, the companies said data from a trial in adult patients showed the booster dose led to a substantial increase in neutralising antibody levels against the BA.4/BA.5 variants after one week.

Omicron-tailored shots made by Pfizer and Moderna Inc have already been given the green light by several countries, including in the United States for adults and, more recently, for children as young as 5 years.



Leave a Reply

Your email address will not be published. Required fields are marked *

Quick links:
Filmi Galbaat

India News



View in punjabi

Follow Us